Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-03-29
2010-11-30
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S510000, C514S320000, C514S354000
Reexamination Certificate
active
07842716
ABSTRACT:
The present invention relates to new methods for treating and/or preventing vascular events by inhibiting G-coupled Protease Activating Receptor (PAR)-1 and/or PAR-4 with the administration of statins. In one embodiment, individuals who are at risk for vascular events, but have cholesterol levels (e.g., total cholesterol or Low Density Lipoprotein) in normal ranges, are treated with statins.
REFERENCES:
patent: 6180660 (2001-01-01), Whitney et al.
Gershlick et al. Recent advances: treament of myocardial infarction. BMJ, 316, pp. 280-284, 1998.
Birnbaum et al. Reduction of infarct size by short-term pretreatment with atorvastatin. Cardiovascular Drugs and Therapy, 17, 25-30, 2003.
Serebruany VL, et al., Absence of Interaction Between Atorvastatin and Clopidogrel in Prospective Data: The Interaction of Atorvastatin and Clopidogrel (INTERACTION Study).European Heart Journal; vol. 24 Suppl: 404 (Mar. 31, 2003).
Serebruany, Victor L., et al.,Thrombosis Res. 113(3-4): 197-204 (2004).
Saw, J. et al., Lack of Adverse clopidogrel-atorvastatin Clinical Interaction . . . ,Circulation108(8):921-4 (2003).
Serebruany, Victor L. et al., Effects of Clopidogrel and aspirin combination . . . ,Am Heart J. 146(4) 713-20 (2003).
Serebruany, Victor L. et al.,Circulation, 107(12):1568-1569 (Apr. 1, 2003).
Hebert, PR et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.JAMA. 278: 1660-1661 (1997).
Serruys, PW et al. Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.JAMA. 287: 3215-3222 (2002).
Sotiriou CG, Cheng JW. Beneficial effects of statins in coronary artery disease—beyond lowering cholesterol.Ann Pharmacother. 34:1432-1439 (2000).
Takemolot, Masao et al., Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.Arterioscler Thromb Vase Biol.; 21:1712-1719 (2001).
Sanguigni V. et al., Increased superoxide anion production by platelets in hypercholesterolemic patients.Thromb Haemost. 87:796-801 (2002).
Vu T-K.H., et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation.Cell. 64: 1057-1068 (1991).
Kahn ML, et al. Protease activated receptors 1 and 4 mediate activation of human platelets by thrombin.Clin Invest. 103: 879-887 (1999).
Brass LF, et al. Changes in the structure and function of the human thrombin receptor during receptor activation, internalization, and recycling.J Biol Chem. 269: 2934-2952 (1994).
Puccetti L, et al. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.Nutr Metab Cardiovasc Dis. 11: 378-387 (2001).
Savi P, et al. Identification and biological activity of the active metabolite of clopidogrel.Thromb Haemost. 84:891-896 (2000).
Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.Clin Pharmacokinet. 41:343-370 (2002).
Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.Drug Metabol Dispos. 31: 53-59 (2002).
Chambers RC, et al., Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1.J Biol Chem. Nov. 10;275(45):35584-91 (2000).
Phillips DR. Thrombin interaction with human platelets: potentiation of thrombin-induced aggregation and release by inactivated thrombin.Thromb Diathesis Haemorrhag. 32:207-215 (1974).
Pilcher BK, Thrombin stimulates fibroblast-mediated collagen lattice contraction by its proteolytically activated receptor.Exp Cell Res. 211:368-373 (1994).
Sower LE, Froelich CJ, Carney DH, Fenton JW II, Klimpel GR. Thrombin induces IL-6 production in fibroblasts and epithelial cells: evidence for the involvement of the seven-transmembrane domain (STD) receptor for -thrombin.J Immunol. 155:895-901 (1995).
Rabiet M, Plantier J, Rival Y, Genoux Y, Lampugnani M, Del Mar EG. Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization.Arterioscler Thromb Vasc Biol. 16:488-496 (1996).
Kinlough-Rathbone RL, Rand ML, Packham MA. Rabbit and rat platelets do not respond to thrombin receptor peptides that activate human platelets.Blood. 82:103-106 (1993).
Henriksen RA, Samokhin GP, Tracy PB. Thrombin-induced thromboxane synthesis by human platelets. Properties of anion binding exosite I-independent receptor.Arterioscler Thromb Vase Biol. 17(12): 3519-26 (1997).
Weksler, B. B., C. W. Ley, and E. A. Jaffe. Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A23187.J. Clin. Invest. 62: 923-930 (1978).
Sugama, Y., C. Tiruppathi, K. Janakidevi, T. T. Andersen, J. W. Fenton II, and A. B. Malik. Thrombin-induced expression of endothelial P-selectin and intercellular adhesion molecule-1: a mechanism for stabilizing neutrophil adhesion.J. Cell Biol. 119: 935-944 (1992).
Tannous, M. et al. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects.Thromb Haemost. 82:1390-1394 (1999).
Puccetti, L. et al. Time-dependent effect of statins on platelet function in hypercholesterolaemia.Eur J Clin Invest. 32: 901-908 (2002).
De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets.J Biol Chem. 276(7):4692-8 (2001).
Kahn, M. L. , Diacovo, T. G. , Bainton, D. F. , Lanza, F. , Trejo, J. & Coughlin, S. R.Blood94, 4112-4121 (1999).
Ramakrishnan, V. , Reeves, P. S. , DeGuzman, F. , Deshpande, U. , Ministri-Madrid, K. , DuBridge, R. B. & Phillips, D. R.Proc. Natl. Acad. Sci. USA96, 13336-13341 (1999).
Ramakrishnan, V. , DeGuzman, F. , Bao, M. , Hall, S. W. , Leung, L. L. & Phillips, D. R.Proc. Nat. Acad. Sci. USA98, 1823-1828 (2001).
Roth GJ, “A new “kid” on the platelet thrombin receptor “block”: glycoprotein Ib-IX-V”Proc Natl Acad Sci U S A98(4):1330-1 (2001).
Neubauer, Horst, et al.,European Heart J. 24(19):1744 (Oct. 2003).
Saucedo, Jorge F., et al.,Circulation108 (17 supplement):IV-579 (Oct. 28, 2003).
Muller, Iris, et al.,Circulation108(18):2195-2197 (Nov. 4, 2003).
Olvotti, L., et al. High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes.Blood Coag Fibrin. 13:315-322 (2002).
Gaddam, V., et al,J. Cardiovascular Pharm&Therap, 7(4):247-253 (Oct. 2002).
Puccetti, L. et al.,European J of Clinical Investig., 32(12):901-908 (Dec. 2002).
Laufs, U et al., Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice.Stroke10:2442-2449 (2000).
Law, Wei C.., et al.,Circulation, 102(18 supplement):II.429 (Oct. 31, 2000).
Lau, WC, et alCirculation, 107(1):32-37 (2003).
Serebrauny, Victor L., MD, PhD. Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel.Archives of Internal Medicine. 2004; 164; 2051-2057.
Fetterolf Brandon J
Giugliano PC Antoinette G
HeartDrug Research, LLC
Pagonakis Anna
LandOfFree
Treating vascular events with statins by inhibiting PAR-1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating vascular events with statins by inhibiting PAR-1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating vascular events with statins by inhibiting PAR-1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4190275